Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest™) and transient elastography (FibroScan®).
Poynard T, Vergniol J, Ngo Y, Foucher J, Munteanu M, Merrouche W, Colombo M, Thibault V, Schiff E, Brass CA, Albrecht JK, Rudler M, Deckmyn O, Lebray P, Thabut D, Ratziu V, de Ledinghen V; FibroFrance Study Group; Epic3 Study Group; Bordeaux HCV Study Group. Poynard T, et al. Among authors: ngo y. J Hepatol. 2014 Apr;60(4):706-14. doi: 10.1016/j.jhep.2013.11.016. Epub 2013 Nov 26. J Hepatol. 2014. PMID: 24291240
Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI c'est fini ?".
Perazzo H, Pais R, Munteanu M, Ngo Y, Monneret D, Imbert-Bismut F, Moussalli J, Lebray P, Benhamou Y, Thabut D, Ratziu V, de Ledhingen V, Poynard T; FibroFrance Group; EPIC3 Group. Perazzo H, et al. Among authors: ngo y. Clin Res Hepatol Gastroenterol. 2014 Sep;38(4):432-9. doi: 10.1016/j.clinre.2014.04.006. Epub 2014 Jun 9. Clin Res Hepatol Gastroenterol. 2014. PMID: 24924901
Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest®) and elastography (FibroScan®).
Poynard T, Vergniol J, Ngo Y, Foucher J, Thibault V, Munteanu M, Merrouche W, Lebray P, Rudler M, Deckmyn O, Perazzo H, Thabut D, Ratziu V, de Ledinghen V; FibroFrance Study Group and the Bordeaux HBV Study Group. Poynard T, et al. Among authors: ngo y. J Hepatol. 2014 Nov;61(5):994-1003. doi: 10.1016/j.jhep.2014.06.027. Epub 2014 Jul 10. J Hepatol. 2014. PMID: 25016224
Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.
Munteanu M, Pais R, Peta V, Deckmyn O, Moussalli J, Ngo Y, Rudler M, Lebray P, Charlotte F, Thibault V, Lucidarme O, Ngo A, Imbert-Bismut F, Housset C, Thabut D, Ratziu V, Poynard T; FibroFrance Group. Munteanu M, et al. Among authors: ngo y, ngo a. Aliment Pharmacol Ther. 2018 Nov;48(10):1117-1127. doi: 10.1111/apt.14990. Epub 2018 Oct 17. Aliment Pharmacol Ther. 2018. PMID: 30334263 Free PMC article.
Diagnostic value of FibroTest with normal serum aminotransferases.
Poynard T, Munteanu M, Ngo Y, Torres M, Benhamou Y, Thabut D, Ratziu V. Poynard T, et al. Among authors: ngo y. Hepatology. 2006 Feb;43(2):374-5; author reply 375-6. doi: 10.1002/hep.21086. Hepatology. 2006. PMID: 16440358 No abstract available.
123 results